Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Multiple Sclerosis

Free Subscription Articles published in J Neuroimmunol Retrieve available abstracts of 101 articles: HTML format

Single Articles

February 2026
1. BUNGANIC R, Revendova KZ, Hradilek P, Kusnierova P, et al
   Comparison of SIMOA and VEUS technologies for serum glial fibrillary acidic protein measurement.
   J Neuroimmunol. 2026;411:578825.
   PubMed     Abstract available
   
   
   January 2026
2. OSTROVSKY A, Simon AJ, Kaplan B
   Free light chains analysis in cerebrospinal fluid for the diagnosis of multiple sclerosis: A study in the Israeli population.
   J Neuroimmunol. 2026;413:578873.
   PubMed     Abstract available
   
   
   
3. BIANCO A, Russo R, Cicia A, Marini S, et al
   Wash-out duration and lymphocyte count in switching from fingolimod to ofatumumab: A case report and literature review.
   J Neuroimmunol. 2026;410:578808.
   PubMed     Abstract available
   
   
   
4. RANIERI G, Chiarugi A, Buonvicino D
   Early exposure of NOD/ShiLtJ mice to Freund's adjuvant prompts delayed, spontaneous progressive encephalomyelitis.
   J Neuroimmunol. 2026;410:578809.
   PubMed     Abstract available
   
   
   
5. PALMER AL, Wang R, Zonta YR, Bailey ZDJ, et al
   Cytokine and chemokine production by astrocytes is influenced by Cystatin C.
   J Neuroimmunol. 2026;410:578801.
   PubMed     Abstract available
   
   
   
6. ALEXAKI A, Baltoumas F, Tzanetakos D, Zografou C, et al
   B cell tolerance checkpoint function in multiple sclerosis and transient CD52 depletion.
   J Neuroimmunol. 2026;413:578854.
   PubMed     Abstract available
   
   
   December 2025
7. ABDELGAIED MY, Abdelgawad O, Rashad MH, Solayman MH, et al
   Efficacy and tolerability of metformin as an adjuvant therapy in patients with relapse-remitting multiple sclerosis receiving interferon Beta 1a: A randomized pilot trial.
   J Neuroimmunol. 2025;412:578852.
   PubMed     Abstract available
   
   
   
8. ULUC F, Ceylan D, Turkoglu SA
   Pilot analysis of Chitinase-3-like protein 1 and soluble Syndecan-1 CSF levels as potential biomarkers in relapsing-remitting multiple sclerosis.
   J Neuroimmunol. 2025;411:578836.
   PubMed     Abstract available
   
   
   November 2025
9. OREFICE NS, Amoriello R, Maghrebi O, Ballerini C, et al
   Early response in cytokine and miR-124a, -125b, -223 expression to anti-CD20 in Multiple Sclerosis and its animal model - a preliminary analysis.
   J Neuroimmunol. 2025;411:578823.
   PubMed     Abstract available
   
   
   
10. MIYAZAKI Y, Yokote H, Fujimori J, Sakurai K, et al
    Wearable-based physiological monitoring and brain magnetic resonance imaging metrics in multiple sclerosis: A feasibility study.
    J Neuroimmunol. 2025;410:578819.
    PubMed     Abstract available
    
    
    October 2025
11. DAGHLAS I, Pluvinage JV, Gill D
    Genetically reduced MTHFR activity confers protection against multiple sclerosis.
    J Neuroimmunol. 2025;410:578784.
    PubMed     Abstract available
    
    
    
12. DITLEVSEN REGEN E, Victor D, Hendrikx T
    Neoehrlichiosis in patients with multiple sclerosis in Halmstad, Sweden: A case series.
    J Neuroimmunol. 2025;410:578787.
    PubMed     Abstract available
    
    
    
13. NATHOO N, Neyal N, Son J, Schwarz CG, et al
    The hidden toll: Atrophy of key central nervous system relays in African American women with multiple sclerosis.
    J Neuroimmunol. 2025;409:578776.
    PubMed     Abstract available
    
    
    September 2025
14. GOUZOUASIS V, Tsifintaris M, Tastsoglou S, Markoglou N, et al
    Epstein-Barr virus reactivation is associated with altered immune cell profiles in peripheral blood and cerebrospinal fluid of treatment-naive multiple sclerosis patients.
    J Neuroimmunol. 2025;409:578758.
    PubMed     Abstract available
    
    
    
15. HANSEN MM, El Mahdaoui S, Hansen MB, Hvalkof VH, et al
    Mononuclear phagocytes in blood and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis: Untreated and treated with anti-CD20 therapy.
    J Neuroimmunol. 2025;409:578751.
    PubMed     Abstract available
    
    
    August 2025
16. TANG Y, Wang H, Wang X, Yan Z, et al
    Characterizing the relationship between FLAIR hyper-rim lesions and paramagnetic rim lesions in multiple sclerosis.
    J Neuroimmunol. 2025;408:578738.
    PubMed     Abstract available
    
    
    
17. BICIMVEREN MS, Ciftci SN, Alp G
    A rare cause of visual impairment in patients with multiple sclerosis: Uveitis.
    J Neuroimmunol. 2025;407:578714.
    PubMed     Abstract available
    
    
    July 2025
18. YANG C, Jiang X, Cheng Z, Zheng C, et al
    Neuroprotective effects of Analgecine by modifying cholesterol metabolism in EAE mice model of multiple sclerosis.
    J Neuroimmunol. 2025;407:578704.
    PubMed     Abstract available
    
    
    
19. SAXENA S, Zhirova A, Krishnan R, Healy B, et al
    SARS-CoV-2 spike antibody and T cell response in MS patients on high efficacy therapies post vaccine.
    J Neuroimmunol. 2025;407:578694.
    PubMed     Abstract available
    
    
    
20. AKOWUAH PK, Botchway E, Owusu E, Ohene DA, et al
    Are corneal nerve and dendritic cell parameters assessed via corneal confocal microscopy good markers for multiple sclerosis? - A systematic review and meta-analysis.
    J Neuroimmunol. 2025;407:578697.
    PubMed     Abstract available
    
    
    
21. GOMEZ FP, Bake S, Young CR, Sohrabji F, et al
    Therapeutic effects of estrogens on inflammatory demyelination in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2025;407:578698.
    PubMed     Abstract available
    
    
    
22. KAUR G, Kumari P, Devi P, Swaminathan A, et al
    Gut dysbiosis influences the pathophysiology of multiple sclerosis: A case-control study from North India.
    J Neuroimmunol. 2025;407:578696.
    PubMed     Abstract available
    
    
    June 2025
23. WELSH NC, DiSano KD, Pike SC, Linzey M, et al
    Network analysis of intrathecally synthesized proteins to unravel mechanisms of disease course in multiple sclerosis.
    J Neuroimmunol. 2025;406:578678.
    PubMed     Abstract available
    
    
    
24. NASEER MA, Hegazy M, El-Mehdawy KM, Ashraf H, et al
    Serum levels of tumor necrosis factor and TNFRSF1A gene polymorphisms in Egyptian multiple sclerosis patients: the influence on susceptibility and severity.
    J Neuroimmunol. 2025;406:578672.
    PubMed     Abstract available
    
    
    
25. ZIVOTIC I, Kolic I, Stefanovic M, Stefanovic NM, et al
    Association of TGFB1 and IFNB1 expression levels in peripheral blood mononuclear cells with multiple sclerosis with respect to proximal rs1800469 and rs2275888 eQTLs.
    J Neuroimmunol. 2025;406:578666.
    PubMed     Abstract available
    
    
    April 2025
26. DEFFENBAUGH JL, Jung KJ, Murphy SP, Liu Y, et al
    Corrigendum to "Novel model of multiple sclerosis induced by EBV-like virus generate a unique B cell population" [Journal of Neuroimmunology volume 394 (2024) 578408].
    J Neuroimmunol. 2025;404:578625.
    PubMed    
    
    
    
27. MASI F, Al Qudsi S, Visigalli D, Zardini E, et al
    Oligoclonal IgM band patterns in multiple sclerosis: A two-center study.
    J Neuroimmunol. 2025;404:578622.
    PubMed     Abstract available
    
    
    
28. EL MAHDAOUI S, Husted SR, Hansen MB, Cobanovic S, et al
    Corrigendum to "Cerebrospinal fluid soluble CD27 is associated with CD8+ T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis" [Journal of neuroimmunology vol. 381 (2023): 578128].
    J Neuroimmunol. 2025;403:578607.
    PubMed    
    
    
    
29. PETROU P, Kassis I, Levi Y, Yaghmour N, et al
    Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01).
    J Neuroimmunol. 2025;403:578613.
    PubMed     Abstract available
    
    
    
30. MARQUES RF, Pedrosa DA, Talim N, Lemos JC, et al
    Relapsing-remitting multiple sclerosis as a potential consequence of thalidomide treatment: A case report.
    J Neuroimmunol. 2025;404:578606.
    PubMed     Abstract available
    
    
    March 2025
31. ZEYDAN B, Neyal N, Nathoo N, Rangachari M, et al
    Effects of androgen modifying therapies on disease activity in older men with multiple sclerosis.
    J Neuroimmunol. 2025;403:578589.
    PubMed     Abstract available
    
    
    
32. CHUANG TY, LaBarre BA, Corbali O, Healy BC, et al
    Endocrine disrupting chemicals in early MS disease activity.
    J Neuroimmunol. 2025;400:578546.
    PubMed     Abstract available
    
    
    February 2025
33. KHEDR EM, Hassan MM, Ezzeldeen MY, El-Kady MS, et al
    Motor symptoms at onset and manual dexterity predict cognitive impairment in drug-naive individuals with multiple sclerosis.
    J Neuroimmunol. 2025;401:578571.
    PubMed     Abstract available
    
    
    
34. YAN Z, Yang X, Lin B, Zhu Q, et al
    Brain network alteration was associated with 'no evidence of disease activity' status in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2025;400:578549.
    PubMed     Abstract available
    
    
    
35. CULINA S, Commere PH, Turc E, Jouy A, et al
    MicroRNA signatures of CD4(+) T cell subsets in healthy and multiple sclerosis subjects determined by small RNA-sequencing.
    J Neuroimmunol. 2025;401:578531.
    PubMed     Abstract available
    
    
    January 2025
36. RANDHAWA G, Mobarakabadi M, D'Mello C, Morch MT, et al
    Targeting extracellular matrix components to attenuate microglia neuroinflammation: A study of fibulin-2 and CSPGs in a model of multiple sclerosis.
    J Neuroimmunol. 2025;400:578533.
    PubMed     Abstract available
    
    
    
37. ETEMADIFAR M, Aghili A, Shojaei S, Alaei SA, et al
    Balo concentric sclerosis, an emerging variant of multiple sclerosis: A case-series and literature review.
    J Neuroimmunol. 2025;400:578527.
    PubMed     Abstract available
    
    
    
38. GULEC B, Everest E, Uygunoglu U
    Letter to the Editor Regarding "Spinocerebellar ataxia masquerading as multiple sclerosis, a case report".
    J Neuroimmunol. 2025;399:578523.
    PubMed    
    
    
    December 2024
39. GURSKI CJ, Hajiyeva Z, Veltri AJ, Fenton K, et al
    Corrigendum to "Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels are B cell depletion with Ocrelizumab" [J. Neuroimmunol. 339:578502 (2024)].
    J Neuroimmunol. 2024;399:578519.
    PubMed    
    
    
    
40. LIANG Y, Huang J, Zhang X, Xu F, et al
    Quantitative assessment of thalamic damage and serum neurofilament light chain in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2024;399:578504.
    PubMed     Abstract available
    
    
    
41. GURSKI CJ, Hajiyeva Z, Veltri AJ, Fenton K, et al
    Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels after B cell depletion with Ocrelizumab.
    J Neuroimmunol. 2024;399:578502.
    PubMed     Abstract available
    
    
    November 2024
42. OZKOSAR A, Oktelik FB, Gelmez MY, Ozturk Erden S, et al
    Retinoic acid modulates peripheral blood helper innate lymphoid cell composition in vitro in patients with multiple sclerosis.
    J Neuroimmunol. 2024;398:578489.
    PubMed     Abstract available
    
    
    September 2024
43. BAI G, Bai Y, Guan H, Ren H, et al
    A case report of lymphoproliferative disease in brain following therapies with mycophenolate Mofetil and Fingolimod and literature review.
    J Neuroimmunol. 2024;394:578410.
    PubMed     Abstract available
    
    
    
44. XU Y, Wei Y, Shi Z, Yin F, et al
    Multimodal magnetic resonance longitudinal study on the deep gray matter in multiple sclerosis patients with teriflunomide.
    J Neuroimmunol. 2024;396:578445.
    PubMed     Abstract available
    
    
    August 2024
45. ABOSEIF A, Amin M, Macaron G, Ontaneda D, et al
    Discordance of reported multiple sclerosis clinical course amongst patients and providers.
    J Neuroimmunol. 2024;395:578443.
    PubMed     Abstract available
    
    
    
46. BILEK F, Ercan Z, Deniz G, Ozgul S, et al
    High-intensity intermittent exercise increases serum levels of chitinase 3-like protein-1 and matrix metalloproteinase-9 in persons with multiple sclerosis.
    J Neuroimmunol. 2024;395:578434.
    PubMed     Abstract available
    
    
    
47. KRIEGER S, Zarif M, Bumstead B, Buhse M, et al
    Evaluating the effect of dimethyl fumarate on subclinical biomarkers in a real-world patient cohort.
    J Neuroimmunol. 2024;393:578397.
    PubMed     Abstract available
    
    
    
48. LEHIKOINEN J, Strandin T, Parantainen J, Nurmi K, et al
    Fibrinolysis associated proteins and lipopolysaccharide bioactivity in plasma and cerebrospinal fluid in multiple sclerosis.
    J Neuroimmunol. 2024;395:578432.
    PubMed     Abstract available
    
    
    
49. ETEMADIFAR M, Alaei SA, Sedaghat N, Ghandehari AH, et al
    TEMPORARY REMOVAL: Pure spinal multiple sclerosis: A case series of a possible new entity.
    J Neuroimmunol. 2024 Aug 8:578429. doi: 10.1016/j.jneuroim.2024.578429.
    PubMed    
    
    
    
50. TORTOSA-CARRERES J, Cubas-Nunez L, Piqueras M, Castillo-Villalba J, et al
    Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
    J Neuroimmunol. 2024;394:578428.
    PubMed     Abstract available
    
    
    July 2024
51. WUERCH EC, Mirzaei R, Yong VW
    Niacin produces an inconsistent treatment response in the EAE model of multiple sclerosis.
    J Neuroimmunol. 2024;394:578421.
    PubMed     Abstract available
    
    
    
52. DEFFENBAUGH JL, Jung KJ, Murphy SP, Liu Y, et al
    Novel model of multiple sclerosis induced by EBV-like virus generates a unique B cell population.
    J Neuroimmunol. 2024;394:578408.
    PubMed     Abstract available
    
    
    
53. YOKOTE H, Miyazaki Y, Fujimori J, Nishida Y, et al
    Characterization of Japanese multiple sclerosis patients with progression independent of relapse activity: A 2-year multicenter cohort study.
    J Neuroimmunol. 2024;394:578407.
    PubMed     Abstract available
    
    
    June 2024
54. RECHTMAN A, Zveik O, Haham N, Brill L, et al
    A protective effect of lower MHC-II expression in MOGAD.
    J Neuroimmunol. 2024;391:578351.
    PubMed     Abstract available
    
    
    
55. WHEELER D, Bezih M, Lannen N
    Spinocerebellar ataxia masquerading as multiple sclerosis, a case report.
    J Neuroimmunol. 2024;393:578385.
    PubMed    
    
    
    
56. YONG HYF, Batty NJ, Tottenham I, Koch M, et al
    Soluble adhesion molecules: Cognitive worsening biomarkers in primary progressive multiple sclerosis?
    J Neuroimmunol. 2024;393:578384.
    PubMed    
    
    
    May 2024
57. SRIRAM S, Kim KW, Ljunggren-Rose A
    Targeted DeSUMOylation as a therapeutic strategy for multiple sclerosis.
    J Neuroimmunol. 2024;392:578371.
    PubMed     Abstract available
    
    
    
58. GELIBTER S, Saraceno L, Pirro F, Susani EL, et al
    As time goes by: Treatment challenges in elderly people with multiple sclerosis.
    J Neuroimmunol. 2024;391:578368.
    PubMed     Abstract available
    
    
    April 2024
59. LI S, Sun D, Wang R, Du Q, et al
    Causal association between multiple sclerosis and severe COVID-19: A bidirectional Mendelian randomization study.
    J Neuroimmunol. 2024;391:578352.
    PubMed    
    
    
    
60. LI V, Binder MD, Purcell AW, Kilpatrick TJ, et al
    Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis.
    J Neuroimmunol. 2024;390:578347.
    PubMed     Abstract available
    
    
    
61. MUNZ C
    Altered EBV specific immune control in multiple sclerosis.
    J Neuroimmunol. 2024;390:578343.
    PubMed     Abstract available
    
    
    March 2024
62. HAHAM N, Zveik O, Rechtman A, Brill L, et al
    Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD.
    J Neuroimmunol. 2024;388:578289.
    PubMed     Abstract available
    
    
    
63. CHANG EH, Hardy TA
    Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
    J Neuroimmunol. 2024;389:578330.
    PubMed     Abstract available
    
    
    
64. FOGEL A, Olcer M, Goel A, Feng X, et al
    Novel biomarkers and interferon signature in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2024;389:578328.
    PubMed     Abstract available
    
    
    February 2024
65. SRIWASTAVA S, Elkhooly M, Amatya S, Shrestha K, et al
    Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis.
    J Neuroimmunol. 2024;390:578315.
    PubMed     Abstract available
    
    
    
66. LOTFI A, Abbasi M, Karami N, Arghavanfar H, et al
    Effects of treadmill training on myelin proteomic markers and cerebellum morphology in a rat model of cuprizone-induced toxic demyelination.
    J Neuroimmunol. 2024;387:578286.
    PubMed     Abstract available
    
    
    
67. SERAFINI B, Benincasa L, Rosicarelli B, Aloisi F, et al
    EBV infected cells in the multiple sclerosis brain express PD-L1: How the virus and its niche may escape immune surveillance.
    J Neuroimmunol. 2024;389:578314.
    PubMed     Abstract available
    
    
    
68. FRID K, Usmann A, Markovits-Pachter T, Binyamin O, et al
    Granagard administration prolongs the survival of human mesenchymal stem cells transplanted into a mouse model of multiple sclerosis.
    J Neuroimmunol. 2024;389:578313.
    PubMed     Abstract available
    
    
    
69. GALETTA K, Ham AS, Vishnevetsky A, Bhattacharyya S, et al
    Disease modifying therapy in the treatment of tumefactive multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2024;388:578299.
    PubMed     Abstract available
    
    
    January 2024
70. PETERSEN-CHERUBINI CL, Liu Y, Deffenbaugh JL, Murphy SP, et al
    Dysregulated autotaxin expression by T cells in multiple sclerosis.
    J Neuroimmunol. 2024;387:578282.
    PubMed     Abstract available
    
    
    
71. FUJIMORI J, Nakashima I
    Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
    J Neuroimmunol. 2024;387:578280.
    PubMed     Abstract available
    
    
    December 2023
72. BAEVA ME, Tottenham I, Koch M, Camara-Lemarroy C, et al
    Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
    J Neuroimmunol. 2023;387:578268.
    PubMed     Abstract available
    
    
    
73. STAVROGIANNI K, Kitsos DK, Giannopapas V, Chasiotis AK, et al
    Neuropsychological profiles comparison between Multiple Sclerosis patients and Multiple Sclerosis patients with overlapping features of Systemic Lupus Erythematosus.
    J Neuroimmunol. 2023;387:578270.
    PubMed     Abstract available
    
    
    
74. TESFAGIORGIS Y, Kemal EA, Craig HC, Parham KA, et al
    Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity.
    J Neuroimmunol. 2023 Dec 15:578267. doi: 10.1016/j.jneuroim.2023.578267.
    PubMed     Abstract available
    
    
    November 2023
75. FARAJI J, Bettenson D, Yong VW, Metz GAS, et al
    Early life stress aggravates disease pathogenesis in mice with experimental autoimmune encephalomyelitis: Support for a two-hit hypothesis of multiple sclerosis etiology.
    J Neuroimmunol. 2023;385:578240.
    PubMed     Abstract available
    
    
    October 2023
76. LEAL RATO M, Santos M, de Sa J, Ferreira J, et al
    Comorbid autoimmune disorders in people with multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2023;385:578226.
    PubMed     Abstract available
    
    
    September 2023
77. ROSHAN HM, Valadan R, Hosseini SA, Ajami A, et al
    Specific antibodies to EBNA1 epitopes as risk factors for multiple sclerosis, a systematic review.
    J Neuroimmunol. 2023;383:578202.
    PubMed     Abstract available
    
    
    
78. CHHABRA S, Mehan S, Khan Z, Gupta GD, et al
    Matrine mediated neuroprotective potential in experimental multiple sclerosis: Evidence from CSF, blood markers, brain samples and in-silico investigations.
    J Neuroimmunol. 2023;384:578200.
    PubMed     Abstract available
    
    
    
79. GELIBTER S, Pirro F, Saraceno L, Susani E, et al
    Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
    J Neuroimmunol. 2023;383:578199.
    PubMed     Abstract available
    
    
    
80. PERDAENS O, van Pesch V
    MicroRNAs are dysregulated in peripheral blood mononuclear cells in multiple sclerosis and correlate with T cell mediators.
    J Neuroimmunol. 2023;386:578196.
    PubMed     Abstract available
    
    
    August 2023
81. KHAN E, Kagzi Y, Elkhooly M, Surpur S, et al
    Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2023;383:578178.
    PubMed     Abstract available
    
    
    
82. BALAZS I, Horvath A, Heschl B, Khalil M, et al
    Anti-CD20 treatment and neutrophil function in central nervous system demyelinating diseases.
    J Neuroimmunol. 2023;381:578136.
    PubMed     Abstract available
    
    
    
83. SOTTINI A, Quaresima V, Barbaro M, Moiola L, et al
    Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab.
    J Neuroimmunol. 2023;382:578170.
    PubMed     Abstract available
    
    
    
84. BRUNE-INGEBRETSEN S, Hogestol EA, de Rosbo NK, Berg-Hansen P, et al
    Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis.
    J Neuroimmunol. 2023;382:578175.
    PubMed     Abstract available
    
    
    July 2023
85. ADAMEC I, Brecl Jakob G, Rajda C, Drulovic J, et al
    Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
    J Neuroimmunol. 2023;382:578164.
    PubMed     Abstract available
    
    
    
86. PRIEGO M, Noriega L, Kalinin S, Hoffman LM, et al
    Genetic deletion of c-Jun amino-terminal kinase 3 (JNK3) modestly increases disease severity in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2023;382:578152.
    PubMed     Abstract available
    
    
    June 2023
87. ELKJAER ML, Lohse RM, Burton M, Mendoza JP, et al
    Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial.
    J Neuroimmunol. 2023;381:578145.
    PubMed     Abstract available
    
    
    
88. BLASK C, Schulze J, Rumpel S, Susse M, et al
    Modulation of cytokine release from peripheral blood mononuclear cells from multiple sclerosis patients by coenzyme A and soraphen A.
    J Neuroimmunol. 2023;381:578135.
    PubMed     Abstract available
    
    
    
89. SI W, Ni Y, Jiang Q, Tan L, et al
    Nanopore sequencing identifies differentially methylated genes in the central nervous system in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2023;381:578134.
    PubMed     Abstract available
    
    
    
90. CARIA P, Pilotto S, D'Alterio MN, Fronza M, et al
    Leukocyte telomere length in women with multiple sclerosis: Comparison with healthy women during pregnancy and puerperium.
    J Neuroimmunol. 2023;381:578137.
    PubMed     Abstract available
    
    
    
91. MICHETTI L, Maffina F, Ravasio R, Barcella V, et al
    Free light chains as a reliable biomarker of intrathecal synthesis in the diagnosis of CNS inflammatory diseases.
    J Neuroimmunol. 2023;379:578091.
    PubMed     Abstract available
    
    
    
92. EL MAHDAOUI S, Husted SR, Hansen MB, Cobanovic S, et al
    Cerebrospinal fluid soluble CD27 is associated with CD8(+) T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2023;381:578128.
    PubMed     Abstract available
    
    
    May 2023
93. MARSTERS C, Nathoo N, Amatto L, Wong R, et al
    Normocomplementemic urticarial vasculitis in a patient with multiple sclerosis on glatiramer acetate.
    J Neuroimmunol. 2023;380:578110.
    PubMed     Abstract available
    
    
    
94. GE A, Sun Y, Kiker T, Zhou Y, et al
    A metabolome-wide Mendelian randomization study prioritizes potential causal circulating metabolites for multiple sclerosis.
    J Neuroimmunol. 2023;379:578105.
    PubMed     Abstract available
    
    
    
95. MANZANO GS, Rice DR, Zurawski J, Jalkh Y, et al
    Familial Mediterranean Fever and multiple sclerosis treated with ocrelizumab: Case report.
    J Neuroimmunol. 2023;379:578099.
    PubMed     Abstract available
    
    
    
96. XUE Y, Zhang L, Guo R, Shao X, et al
    miR-485 regulates Th17 generation and pathogenesis in experimental autoimmune encephalomyelitis through targeting STAT3.
    J Neuroimmunol. 2023;379:578100.
    PubMed     Abstract available
    
    
    April 2023
97. MULLER-MINY L, Heming M, Lautwein T, Ruck T, et al
    Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis.
    J Neuroimmunol. 2023;378:578088.
    PubMed     Abstract available
    
    
    
98. VACARAS V, Muresanu DF, Buzoianu AD, Nistor C, et al
    The role of multiple sclerosis therapies on the dynamic of human gut microbiota.
    J Neuroimmunol. 2023;378:578087.
    PubMed     Abstract available
    
    
    March 2023
99. ABBADESSA G, Miele G, Cavalla P, Valentino P, et al
    Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab.
    J Neuroimmunol. 2023;378:578072.
    PubMed     Abstract available
    
    
    
100. FERREIRA F, Ferreira D, Guimaraes J, Soares-Dos-Reis R, et al
     Recurrent encephalopathy associated with pegylated beta-interferon treatment.
     J Neuroimmunol. 2023;376:578037.
     PubMed     Abstract available
     
     
     
101. PALACIO PL, Pleet ML, Reategui E, Magana SM, et al
     Emerging role of extracellular vesicles in multiple sclerosis: From cellular surrogates to pathogenic mediators and beyond.
     J Neuroimmunol. 2023;377:578064.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.